Tyra Biosciences (NASDAQ:TYRA - Get Free Report) announced its earnings results on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02, Zacks reports.
Tyra Biosciences Price Performance
TYRA stock traded down $0.06 on Thursday, reaching $9.61. 6,608 shares of the company were exchanged, compared to its average volume of 260,310. Tyra Biosciences has a 12 month low of $6.42 and a 12 month high of $29.60. The stock's fifty day moving average price is $9.58 and its 200 day moving average price is $12.97. The firm has a market capitalization of $510.19 million, a PE ratio of -5.96 and a beta of 1.17.
Wall Street Analyst Weigh In
Several research analysts have commented on TYRA shares. Wedbush reiterated an "outperform" rating and issued a $30.00 target price on shares of Tyra Biosciences in a report on Friday, March 28th. HC Wainwright restated a "buy" rating and set a $30.00 price target on shares of Tyra Biosciences in a report on Monday, March 31st. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Tyra Biosciences currently has a consensus rating of "Buy" and an average target price of $30.83.
Check Out Our Latest Report on Tyra Biosciences
About Tyra Biosciences
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Featured Stories
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
